The fuchs endothelial corneal dystrophy market is expected to experience significant growth in the coming years, propelled by the development of innovative non-surgical therapies, an increasing ...

Other groups advanced FGF1 as well as different FGFs ... phase 2 proof-of-concept trial in patients with Fuchs dystrophy in 2021. The phase 2 trial is enrolling Fuchs dystrophy patients who ...

A new discovery about how tiny protein clusters form in cells could pave the way for treatments for Emery-Dreifuss muscular dystrophy (EDMD ... and Sciences combined advanced imaging techniques ...

today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025 ...